2026 Q3 - tulosraportti
11 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,20%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sitten · MuokattuNovo Nordisk gets important progress in China 🇨🇳 China has on November 14, 2026 published an update of the national reimbursement list, which gives Novo Nordisk two positive news within diabetes care. IcoSema gets national reimbursement for the first time -Novo Nordisk's weekly combination treatment of insulin icodec and semaglutide has been included on China's national reimbursement list. -The reimbursement applies to adults with type 2 diabetes where blood sugar is not sufficiently regulated after treatment with basal insulin or GLP-1 receptor agonists. Awiqli gets expanded reimbursement access Awiqli (weekly insulin icodec) has had its reimbursement status renewed. At the same time, the patient group is expanded so more people with type 2 diabetes become eligible for reimbursement. Entry into force: Both changes take effect on January 1, 2027. Strengthened commercial position in China Novo Nordisk has furthermore entered into or expanded strategic partnerships with among others JD Health and Alibaba Health. The purpose is to improve distribution, medicine availability, patient service and digital diabetes care, including AI-based disease management. Significance for Novo Nordisk and the stock -Greater market access: National reimbursement can make the treatments economically accessible for far more Chinese patients. -Strengthened competitive position: IcoSema gets an important commercial advantage by entering one of the world's largest diabetes markets. -Growth potential: The expanded access to Awiqli can support increased patient uptake and sales. -Strategic momentum: The partnerships with JD Health and Alibaba Health can strengthen Novo Nordisk's distribution and digital presence.
Quiet and steady rise in the share price is also achieved, so will be satisfied with 285 tomorrow at 9
·3 t sittenThe great communicator ! Thanks for the rush you gave us this weekend - carried forward by your truthful and scientific presentation. In the coming week, everyone will feel the joy of the golden words from the weekend - and safely embrace the pillow. (A) 👨🏻🎓
·4 t sittenIt has been yet another busy week for Novo Nordisk. I have compiled the most important news of the week in this post: https://x.com/investseekers/status/2122012448739704853?a=-0a53b6ItDyup3EO-6k&s=20
·5 t sittenIs it time to take profits home? Possibly sell the over-spiced one.- ·5 t sittenCagriSema vs. tirzepatide – what do the new numbers show? The new results from Novo Nordisks REDEFINE 1 study show that CagriSema can provide very substantial weight loss in patients who respond quickly to the treatment. The key numbers: * 67.8% of participants lost at least 5% of their weight by week 8. * These early responders achieved an average weight loss of 25.4% after 68 weeks. * The patients who responded more slowly lost an average of 17.8%. How does it stack up against tirzepatide? In SURMOUNT-1, tirzepatide 15 mg achieved an average weight loss of 20.9-22.5%. CagriSema's 25.4% is thus higher, but it is important to remember that the figure only applies to patients who responded quickly. The most interesting thing about the new numbers is that nearly 68% of the participants on CagriSema were early responders and achieved a weight loss of a full 25.4% on average.
Great US close, and great weekend presentations, should give a bid below the share. Have put a buy order in at price 280, which is around where US closed. Normally Novo is sold down in the first hours in DK, so I am hoping.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
11 päivää sitten
‧1 t 3 min
3,75 DKK/osake
Viimeisin osinko
4,20%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sitten · MuokattuNovo Nordisk gets important progress in China 🇨🇳 China has on November 14, 2026 published an update of the national reimbursement list, which gives Novo Nordisk two positive news within diabetes care. IcoSema gets national reimbursement for the first time -Novo Nordisk's weekly combination treatment of insulin icodec and semaglutide has been included on China's national reimbursement list. -The reimbursement applies to adults with type 2 diabetes where blood sugar is not sufficiently regulated after treatment with basal insulin or GLP-1 receptor agonists. Awiqli gets expanded reimbursement access Awiqli (weekly insulin icodec) has had its reimbursement status renewed. At the same time, the patient group is expanded so more people with type 2 diabetes become eligible for reimbursement. Entry into force: Both changes take effect on January 1, 2027. Strengthened commercial position in China Novo Nordisk has furthermore entered into or expanded strategic partnerships with among others JD Health and Alibaba Health. The purpose is to improve distribution, medicine availability, patient service and digital diabetes care, including AI-based disease management. Significance for Novo Nordisk and the stock -Greater market access: National reimbursement can make the treatments economically accessible for far more Chinese patients. -Strengthened competitive position: IcoSema gets an important commercial advantage by entering one of the world's largest diabetes markets. -Growth potential: The expanded access to Awiqli can support increased patient uptake and sales. -Strategic momentum: The partnerships with JD Health and Alibaba Health can strengthen Novo Nordisk's distribution and digital presence.Quiet and steady rise in the share price is also achieved, so will be satisfied with 285 tomorrow at 9
- ·3 t sittenThe great communicator ! Thanks for the rush you gave us this weekend - carried forward by your truthful and scientific presentation. In the coming week, everyone will feel the joy of the golden words from the weekend - and safely embrace the pillow. (A) 👨🏻🎓
- ·4 t sittenIt has been yet another busy week for Novo Nordisk. I have compiled the most important news of the week in this post: https://x.com/investseekers/status/2122012448739704853?a=-0a53b6ItDyup3EO-6k&s=20
- ·5 t sittenIs it time to take profits home? Possibly sell the over-spiced one.
- ·5 t sittenCagriSema vs. tirzepatide – what do the new numbers show? The new results from Novo Nordisks REDEFINE 1 study show that CagriSema can provide very substantial weight loss in patients who respond quickly to the treatment. The key numbers: * 67.8% of participants lost at least 5% of their weight by week 8. * These early responders achieved an average weight loss of 25.4% after 68 weeks. * The patients who responded more slowly lost an average of 17.8%. How does it stack up against tirzepatide? In SURMOUNT-1, tirzepatide 15 mg achieved an average weight loss of 20.9-22.5%. CagriSema's 25.4% is thus higher, but it is important to remember that the figure only applies to patients who responded quickly. The most interesting thing about the new numbers is that nearly 68% of the participants on CagriSema were early responders and achieved a weight loss of a full 25.4% on average.Great US close, and great weekend presentations, should give a bid below the share. Have put a buy order in at price 280, which is around where US closed. Normally Novo is sold down in the first hours in DK, so I am hoping.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q3 - tulosraportti
11 päivää sitten
‧1 t 3 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 3.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 4.11. | ||
2026 Q2 - tulosraportti 5.8. | ||
2026 Q1 - tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 - tulosraportti 4.2. |
Tuotteita joiden kohde-etuutena tämä arvopaperi
3,75 DKK/osake
Viimeisin osinko
4,20%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sitten · MuokattuNovo Nordisk gets important progress in China 🇨🇳 China has on November 14, 2026 published an update of the national reimbursement list, which gives Novo Nordisk two positive news within diabetes care. IcoSema gets national reimbursement for the first time -Novo Nordisk's weekly combination treatment of insulin icodec and semaglutide has been included on China's national reimbursement list. -The reimbursement applies to adults with type 2 diabetes where blood sugar is not sufficiently regulated after treatment with basal insulin or GLP-1 receptor agonists. Awiqli gets expanded reimbursement access Awiqli (weekly insulin icodec) has had its reimbursement status renewed. At the same time, the patient group is expanded so more people with type 2 diabetes become eligible for reimbursement. Entry into force: Both changes take effect on January 1, 2027. Strengthened commercial position in China Novo Nordisk has furthermore entered into or expanded strategic partnerships with among others JD Health and Alibaba Health. The purpose is to improve distribution, medicine availability, patient service and digital diabetes care, including AI-based disease management. Significance for Novo Nordisk and the stock -Greater market access: National reimbursement can make the treatments economically accessible for far more Chinese patients. -Strengthened competitive position: IcoSema gets an important commercial advantage by entering one of the world's largest diabetes markets. -Growth potential: The expanded access to Awiqli can support increased patient uptake and sales. -Strategic momentum: The partnerships with JD Health and Alibaba Health can strengthen Novo Nordisk's distribution and digital presence.Quiet and steady rise in the share price is also achieved, so will be satisfied with 285 tomorrow at 9
- ·3 t sittenThe great communicator ! Thanks for the rush you gave us this weekend - carried forward by your truthful and scientific presentation. In the coming week, everyone will feel the joy of the golden words from the weekend - and safely embrace the pillow. (A) 👨🏻🎓
- ·4 t sittenIt has been yet another busy week for Novo Nordisk. I have compiled the most important news of the week in this post: https://x.com/investseekers/status/2122012448739704853?a=-0a53b6ItDyup3EO-6k&s=20
- ·5 t sittenIs it time to take profits home? Possibly sell the over-spiced one.
- ·5 t sittenCagriSema vs. tirzepatide – what do the new numbers show? The new results from Novo Nordisks REDEFINE 1 study show that CagriSema can provide very substantial weight loss in patients who respond quickly to the treatment. The key numbers: * 67.8% of participants lost at least 5% of their weight by week 8. * These early responders achieved an average weight loss of 25.4% after 68 weeks. * The patients who responded more slowly lost an average of 17.8%. How does it stack up against tirzepatide? In SURMOUNT-1, tirzepatide 15 mg achieved an average weight loss of 20.9-22.5%. CagriSema's 25.4% is thus higher, but it is important to remember that the figure only applies to patients who responded quickly. The most interesting thing about the new numbers is that nearly 68% of the participants on CagriSema were early responders and achieved a weight loss of a full 25.4% on average.Great US close, and great weekend presentations, should give a bid below the share. Have put a buy order in at price 280, which is around where US closed. Normally Novo is sold down in the first hours in DK, so I am hoping.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 2 | ||
| 2 121 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt